This year clinical trial results for PURPOSE 1 and 2 showed the high prevention effectiveness of the 6-monthly long-acting injectable drug, lenacapavir for cisgender adolescent girls and women, ...

In order to counter such stigma and discrimination, women living with HIV and Hepatitis B came together at The Voice of ...

Note: ViiV’s announcement can be read on their site at ...

unaids.org UNAIDS Responding to today’s announcement by Gilead on lenacapavir, UNAIDS Executive Director ...

GENEVA, 8 October 2024—Responding to ViiV’s announcement on long-acting cabotegravir , UNAIDS Executive Director Winnie Byanyima said: “New HIV prevention medication, in the form of a long-acting ...

GENEVA, 8 October 2024—Responding to ViiV’s announcement on long-acting cabotegravir , UNAIDS Executive Director Winnie Byanyima said: “New HIV prevention medication, in the form of a long-acting ...

We welcome Gilead’s statement of commitment to non-profit pricing, but we had been waiting eagerly for a specific price. We ...

GENEVA, 1 October 2024—UNAIDS expresses deep concern over the recently adopted anti-LGBTQ+ legislation in Georgia, which poses serious risks to public health and human rights. UNAIDS supports the UN ...

UNAIDS supports the UN Office for the High Commissioner of Human Rights' statement that these laws will “impose discriminatory restrictions on education, public discussion, and gatherings related to ...

UNAIDS data shows that the end of AIDS as a public health threat is achievable by 2030, if countries, communities and partners close the gaps holding back progress.

As countries transition away from donor assistance and progress towards universal health coverage, there is growing emphasis on the importance of integrating HIV services into national health systems ...